Skip to main content
. 2020 May 27;15:743–754. doi: 10.2147/CIA.S253116

Table 7.

Intervened Participants with Adverse Events by System Organ Class

System Organ Class MKP Placebo P value
(n = 134) (n = 131)
n (%) n (%)
Infections and infestations 52 (38.8) 54 (41.2) 0.708
Nervous system disorders 16 (11.9) 14 (10.7) 0.847
Gastrointestinal disorders 13 (9.7) 15 (11.5) 0.693
Musculoskeletal and connective tissue disorders 7 (5.2) 9 (6.9) 0.615
Respiratory, thoracic and mediastinal disorders 5 (3.7) 8 (6.1) 0.408
General disorders and administration site conditions 2 (1.5) 1 (0.8) 1.000
Injury, poisoning and procedural complications 2 (1.5) 2 (1.5) 1.000
Cardiac disorders 1 (0.7) 1 (0.8) 1.000
Immune system disorders 1 (0.7) 2 (1.5) 0.619
Neoplasms benign, malignant and unspecified 1 (0.7) 2 (1.5) 0.619
Renal and urinary disorders 1 (0.7) 0 (0.0) 1.000
Reproductive system and breast disorders 1 (0.7) 0 (0.0) 1.000
Skin and subcutaneous tissue disorders 1 (0.7) 5 (3.8) 0.117
Ear and labyrinth disorders 0 (0.0) 1 (0.8) 0.494

Note: P values were derived by the Fisher’s exact test.

Abbreviation: MKP, Met-Lys-Pro.